{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:50:40Z","timestamp":1787550640141,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00198-025-07386-4","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T03:43:39Z","timestamp":1736999019000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case\u2013control study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-6724","authenticated-orcid":false,"given":"Toshitaka","family":"Yukishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-5969","authenticated-orcid":false,"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-6780","authenticated-orcid":false,"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-4984","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-8209","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"7386_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"7386_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrendo.2015.71","volume":"11","author":"IR Reid","year":"2015","unstructured":"Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418\u2013428","journal-title":"Nat Rev Endocrinol"},{"key":"7386_CR3","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","volume":"22","author":"J Compston","year":"2011","unstructured":"Compston J (2011) Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 22:2951\u20132961","journal-title":"Osteoporos Int"},{"key":"7386_CR4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769\u20132774","journal-title":"Osteoporos Int"},{"key":"7386_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"7386_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838\u20131845","journal-title":"J Clin Endocrinol Metab"},{"key":"7386_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"7386_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S127568","volume":"11","author":"SY Lim","year":"2017","unstructured":"Lim SY, Bolster MB (2017) Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther 11:1221\u20131231","journal-title":"Drug Des Devel Ther"},{"key":"7386_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"7386_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2023","unstructured":"Kobayakawa T, Miyazaki A, Kanayama Y et al (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33:96\u2013103","journal-title":"Mod Rheumatol"},{"key":"7386_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"7386_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"7386_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"7386_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","volume":"35","author":"K Ebina","year":"2024","unstructured":"Ebina K, Nagayama Y, Kashii M et al (2024) An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. Osteoporos Int 35:841\u2013849","journal-title":"Osteoporos Int"},{"key":"7386_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.joca.2023.07.010","volume":"31","author":"A Goshima","year":"2023","unstructured":"Goshima A, Etani Y, Hirao M et al (2023) Basic fibroblast growth factor promotes meniscus regeneration through the cultivation of synovial mesenchymal stem cells via the CXCL6-CXCR2 pathway. Osteoarthritis Cartilage 31:1581\u20131593","journal-title":"Osteoarthritis Cartilage"},{"key":"7386_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL et al (2016) Best practises for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 19:127\u2013140","journal-title":"J Clin Densitom"},{"key":"7386_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","volume":"29","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hirao M, Hashimoto J et al (2018) Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis. Osteoporos Int 29:1627\u20131636","journal-title":"Osteoporos Int"},{"key":"7386_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"7386_CR19","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"7386_CR20","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomized, open-label, Phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"7386_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M et al (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173\u2013179","journal-title":"Bone"},{"key":"7386_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/03008200802412462","volume":"50","author":"B Jobke","year":"2009","unstructured":"Jobke B, Pfeifer M, Minne HW (2009) Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodelling at the human iliac crest. Connect Tissue Res 50:46\u201354","journal-title":"Connect Tissue Res"},{"key":"7386_CR23","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780","journal-title":"J Clin Endocrinol Metab"},{"key":"7386_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591\u20131600","journal-title":"J Bone Miner Res"},{"key":"7386_CR25","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s00198-022-06545-1","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H et al (2022) Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:2441\u20132443","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07386-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07386-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07386-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:31:10Z","timestamp":1741149070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07386-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7386"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07386-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KE has received research grants from Asahi Kasei, Eisai, and Teijin Pharma and speaker fees from Amgen, Asahi Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono Pharmaceutical, Pfizer, Taisho and UCB Japan. KE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. YE received research grants and\/or speaker fees from Asahi Kasei, Eisai, Eli Lilly, Ono Pharmaceuticals, and Taisho. YE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei.\u00a0KN received a research grant from Astellas and supervises the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei.\u00a0TK has received payments for lectures from AbbVie, Amgen, Asahi Kasei, Astellas, Daiichi Sankyo, Eisai, Eli Lilly, Tanabe-Mitsubishi, Teijin Pharma, and Janssen Pharmaceutical K.K.. TY, TN, Shin-ichiro O, and Seiji O declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}